Clinical trials
Premenopausal Breast Cancer clinical trials
Below are recruiting premenopausal breast cancer clinical trials, each written for real people, not researchers. We’re tracking 123 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07648914RecruitingPhase 3
BL-B01D1 versus chemotherapy for advanced hormone-receptor-positive breast cancer
This trial tests a new targeted drug called BL-B01D1 against standard chemotherapy in patients with advanced breast cancer that is hormone-receptor-positive (HR+) and HER2-negative, and has stopped responding to hormone treatments. The goal is to see if the new drug works better or has fewer side effects.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07354022RecruitingPhase 3
Study of HRS-8080 with dalpiciclib for advanced breast cancer after hormone therapy fails
This trial tests a new combination of drugs (HRS-8080 and dalpiciclib) for women with advanced or metastatic breast cancer that has stopped responding to initial hormone therapy after surgery. It aims to see if this combination is safe and effective.
Beijing, Beijing MunicipalityAges 18–75 - NCT07396454RecruitingPhase 2
Radiation plus anlotinib for HER2-negative breast cancer brain metastases
This trial tests whether adding anlotinib (a targeted therapy) to standard radiation can better control breast cancer that has spread to the brain. It is for people with HER2-negative breast cancer and at least one brain tumor seen on MRI.
NanjingAges 18–70 - NCT06998108RecruitingPhase 3
A new drug with fulvestrant for HR+/HER2- advanced breast cancer
This trial tests a new investigational drug called BEBT-209 combined with fulvestrant (a hormone therapy) versus placebo with fulvestrant for people with a type of breast cancer that is hormone receptor-positive and HER2-negative. It is for those whose cancer has worsened after previous hormone therapy and has spread locally or to other parts of the body.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07287098RecruitingPhase 2
Imlunestrant for premenopausal women with ER+/HER2- early breast cancer
This trial tests a new hormone-blocking pill (imlunestrant) in premenopausal women with early-stage ER+/HER2- breast cancer. Depending on whether you've had prior hormone therapy, the study will see if this treatment works better than standard options.
Birmingham, AlabamaAges 18 years+ - NCT04144907Recruiting
Protein needs study for colorectal or breast cancer
This study tests how much protein people with colorectal or breast cancer need during treatment or recovery. It may help improve nutrition guidance and support for maintaining health during chemo or after surgery.
Edmonton, AlbertaAges 45–80 - NCT04913064Recruiting
White button mushroom supplement for inflammation in high-risk breast cancer
This trial tests whether a white button mushroom powder supplement can lower inflammation in postmenopausal women who have a high risk of breast cancer. If it helps, it could improve early prevention strategies for people at higher risk.
Duarte, CaliforniaAges 21 years+ - NCT07088263RecruitingPhase 3
Adaptive Chemotherapy for Advanced Breast Cancer
This trial tests a new approach to chemotherapy that adapts over time for people with advanced breast cancer that has not responded to first-line treatment. It is designed to personalize treatment based on how the cancer responds, potentially improving outcomes with fewer side effects.
Guangzhou, GuangdongAges 18–75 - NCT06195709RecruitingPhase 3
Study of PET imaging and blood tests for ER+ HER2- metastatic breast cancer
This trial tests a new imaging technique (18F-FES PET/CT) along with blood markers to guide treatment for metastatic breast cancer that is ER-positive and HER2-negative. It's for people whose cancer progressed on first-line hormone therapy and who are starting a second line of hormone therapy.
BayonneAges 18 years+ - NCT06081244RecruitingPhase 3
Testing sacituzumab govitecan with or without pembrolizumab for early triple-negative breast cancer
This trial tests a two-drug combination (sacituzumab govitecan and pembrolizumab) versus sacituzumab govitecan alone before surgery for low-risk, triple-negative breast cancer that hasn't spread. The goal is to see which approach works better at shrinking tumors.
Baden-Baden, Baden-WurttembergAges 18 years+ - NCT07287917RecruitingPhase 1/Phase 2
Testing a new drug combo for advanced breast cancer or melanoma
This trial tests a new combination of drugs (AMXT 1501, DFMO, and standard therapies) for people with advanced solid tumors, specifically breast cancer (ER+ HER2-) or melanoma that has progressed after other treatments. The goal is to see if this combination can help shrink tumors or slow their growth.
Tucson, ArizonaAges 18 years+ - NCT05277935Recruiting
Wearable activity tracking for hormone-positive metastatic breast cancer
This study tests whether using a wearable watch and smartphone app to track activity and fitness can help monitor health in people with hormone receptor–positive, HER2-negative metastatic breast cancer while they take standard hormone therapy plus palbociclib. It mainly requires that you are already on these medicines for at least three months and can use the devices reliably.
Rio de JaneiroAges 18 years+ - NCT07467330RecruitingPhase 3
Breast cancer trial: Adding capecitabine to standard treatment
This trial tests if adding a chemotherapy drug called capecitabine to the combination of dalpiciclib and hormone therapy works better than dalpiciclib and hormone therapy alone for advanced breast cancer that is hormone receptor-positive and HER2-negative. It is for people who have not had these treatments before.
Fuzhou, FujianAges 18 years+ - NCT07383649RecruitingPhase 2
Anti-CMV therapy for breast cancer with brain metastases
This trial tests a treatment targeting a common virus (CMV) in breast cancer that has spread to the brain. The goal is to see if anti-CMV therapy can shrink or slow these brain tumors.
Houston, TexasAges 18 years+ - NCT05910294Recruiting
Preventing and improving sexual health in early breast cancer
This study looks at ways to prevent and treat sexual discomfort in people with hormone-receptor positive breast cancer. It targets women who are not having current vaginal dryness or pain related to lower estrogen, and may help protect sexual comfort during cancer-related hormone treatment.
Basking Ridge, New JerseyAges 18 years+ - NCT06923527RecruitingPhase 2
Testing ctDNA to start elacestrant in early breast cancer
This trial tests whether the drug elacestrant can help prevent recurrence in people with a type of breast cancer (ER+/HER2-) who have finished hormone therapy and have signs of cancer DNA in their blood (ctDNA positive) but no visible spread on scans.
New Haven, ConnecticutAges 18 years+ - NCT06552091Recruiting
Digital self-hypnosis for hot flashes from hormone therapy
This trial tests a guided digital self-hypnosis program to help reduce hot flashes caused by hormone therapy for breast cancer. It aims to see if it can make hot flashes less frequent and bothersome.
Vandœuvre-lès-NancyAges 18 years+ - NCT07426822RecruitingPhase 2
Preventing Rash and Diarrhea with Capivasertib for Breast Cancer
This trial tests whether giving a combination of the drugs capivasertib and fulvestrant, along with medicines to prevent rash and diarrhea, can help treat hormone receptor-positive breast cancer that has a PIK3CA, AKT1, or PTEN change. It's for people whose cancer has spread or is locally advanced and can't be removed with surgery.
New Haven, ConnecticutAges 18 years+ - NCT03561740RecruitingPhase 3
Capecitabine plus usual treatment for high-risk HER2 breast cancer
This trial looks at whether adding a chemotherapy medicine called capecitabine (taken in smaller, regular doses) to the standard after-surgery (adjuvant) treatment can lower the chance of cancer coming back in people with early-stage, high-risk HER2-positive breast cancer. It targets patients who still had cancer left after earlier treatment or who had higher-risk tumor features.
Guangzhou, GuangdongAges 18–70 - NCT04614194RecruitingPhase 2
Blood and tumor markers to test response to abemaciclib
This trial studies how the immune system and other body signals in blood and tumor tissue relate to how well abemaciclib works before breast cancer surgery. The goal is to learn who benefits most from this medicine and why.
Dallas, TexasAges 18 years+ - NCT05217966Recruiting
Radiation before possible breast surgery for early ER-positive cancer
This study gives radiation to the breast before surgery to see if some people can safely delay or even skip surgery. It targets women with a small, node-negative, ER-positive breast cancer with low genetic risk.
Montreal, QuebecAges 50 years+ - NCT05228951RecruitingPhase 2
Testing four breast cancer medicines for stage II–III ER+/PR+/HER2+ cancer
This trial studies a combination of anti-cancer medicines (including trastuzumab and hormone therapy) for women with stage II–III breast cancer that is ER-, PR-, and HER2-positive. It aims to improve outcomes by attacking the cancer in different ways.
Shenyang, LiaoningAges 18–75 - NCT05708235RecruitingPhase 2
Using blood test results to guide breast cancer treatment
This Phase 2 study tests whether doctors can use a blood test (ctDNA) to find breast cancer recurrence risk early and guide further treatment. Depending on your ctDNA result and tumor markers, you may receive standard hormone therapy or one of several additional treatment options.
A CoruñaAges 18 years+ - NCT06200168RecruitingPhase 3
Electroacupuncture to prevent nausea during breast cancer chemo
This study tests whether electroacupuncture can help prevent nausea and vomiting caused by strong chemotherapy in people with breast cancer. If you're starting a certain type of chemo, this could help you feel better during treatment.
Xining, QinghaiAges 18–75
Hear when a new Premenopausal Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for premenopausal breast cancer?
- Yes. Clin2 currently lists 123 recruiting premenopausal breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a premenopausal breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a premenopausal breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.